Novo Nordisk has settled a patent infringement lawsuit against telehealth company Hims & Hers regarding the sale of compounded Wegovy. As part of the agreement, Hims will cease advertising compounded GLP-1 products but will continue to offer them if deemed clinically necessary by a provider. Additionally, Hims will now list brand-name Wegovy on its platform, marking a shift in its business strategy.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.